CandlesenseCandlesense
News/Companies/ADAG

ADAG News

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

ADAG

(NASDAQ:ADAG) SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor.

September 3, 2025Leadership
Read more →

Adagene to Participate in Two Investor Conferences in September

ADAG

SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at two investor conferences in September, both taking place in New York, New York.

August 26, 2025Investor
Read more →

Adagene Files For Offering Of Up To $100M American Depositary Shares Representing Ordinary Shares

ADAG

May 30, 2025
Read more →

Adagene Reveals Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA in Colorectal Cancer At The American Society of Clinical Oncology Annual Meeting

ADAG

May 22, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $8 Price Target

ADAG

April 3, 2025
Read more →

Adagene FY24 Adj. EPS $(0.51) vs $(0.21) YoY; Revenues $103,204

ADAG

March 24, 2025
Read more →

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors

ADAG

September 12, 2022
Read more →

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7

ADAG

September 9, 2022
Read more →